Senior Medical Science Liaison - Southeast

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

This role is a field based, non-promotional medical and scientific role.  The MSLs key objective is to engage scientifically with HCPs and medical experts in support of Kura’s corporate and medical strategies and plans.  The ideal MSL has had experience in AML, HNSCC, or NSCLC and have prior or existing relationships with experts in these areas.  The MSL will also collaborate regularly and effectively with cross-functional colleagues. The southeast territory covers AL, FL, GA, MS, and TN.

ESSENTIAL JOB FUNCTIONS:

• Leverage scientific expertise to establish and maintain strategically impactful relationships with national, regional, and local Acute Myeloid Leukemia (AML) key opinion leaders (KOLs) and other healthcare providers (HCPs) in alignment with medical strategy.
• Proactively and reactively engage KOLs and HCPs on a variety of topics inclusive, but not limited to, disease state, mechanism of action, clinical data, and the evolution of the treatment landscape(s).
• Support asset-specific prelaunch readiness and optimized launch execution through the attainment of impactful qualitative and quantitative field medical metrics.
• Provide internal stakeholders with actionable medical insights from interactions with HCPs.
• Explore potential new areas of interest to understand unmet needs, how the landscape is evolving, and how Kura pipeline products can address unmet needs.
• Collaborate with clinical development/operations to support the potential identification of clinical trial sites/investigators and to heighten awareness of Kura late-stage company sponsored clinical trials.
• Keep abreast of medical and scientific developments in the designated disease areas by continuously reviewing literature in the field, monitoring competitor activities, networking with experts and attending relevant conferences. Complete accurate and timely administrative reports, projects, and other required documentation.
• Deliver approved medical/scientific presentations to internal & external stakeholders.
• Support evidence generation through the facilitation of external investigator-sponsored research concept submissions.
• Regularly and effectively collaborate with field colleagues (e.g., HEOR, market access, regional marketing, sales) within the assigned therapeutic area and territory to advance clinical practice while maintaining customer centricity in a compliant manner.
• Support medical/scientific training of cross functional teams, as needed.
• Adhere to Kura Oncology’s values and policies.

JOB SPECIFICATIONS:

• PharmD/RPh, PhD, NPs, PAs, or a Master’s degree in life sciences with clinical research experience
• 3+ years of field experience in the biotech or pharmaceutical industry, oncology/hematology launch experience preferred
• Oncology/Hematology experience with established relationships with KOLs in therapeutic areas of interest (i.e. AML)
• Strong interpersonal, presentation and communication skills and demonstrated ability to work collaboratively in a dynamic, team-oriented environment
• Demonstrated self-starter and collaborative team player with strong interpersonal skills
• Ability to interpret key scientific data and translate findings to meet educational and research needs
• Able to ensure compliance with corporate rules and government regulations
• Willingness to travel up to 50% of the time, including overnight and weekends

The base range for a Senior MSL is $228,417 - $256,805 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.